Upstream Processing:Vendor Notes: Generating Stable, High-Expressing Cell Lines for Recombinant Protein Manufacture - - BioPharm International


Upstream Processing:Vendor Notes: Generating Stable, High-Expressing Cell Lines for Recombinant Protein Manufacture

BioPharm International
Volume 20, Issue 3

Targeted Integration

Each recombination acceptor cassette on the Platform ACE consists of a lambda phage attP site flanked by a simian virus 40 (SV40) promoter at the 5' position and an open reading frame sequence encoding the puromycin resistance (puromycin) gene at the 3' position. This confers puromycin resistance to cells carrying the Platform ACE (Figure 1A). All ATVs (Figure 1C) encode a bacterial attB site upstream of a promoterless, secondary drug-selectable marker gene (e.g., zeocin, blasticidin, neomycin, or hygromycin), which becomes activated by the SV40 promoter when the ATV integrates correctly via recombination between the attB site on the ATV and an attP site residing on the Platform ACE (Figure 1D). The ATV also contains the target gene cassette, which consists of the gene(s) of interest flanked by insulators and a 5' upstream CX promoter (chicken Beta-actin promoter and CMV immediate/early enhancer). Multiple copies of the same gene or multiple genes (e.g., heavy and light chains of an antibody) can be placed into the ATV and loaded on to the Platform ACE. The site-specific recombination is mediated by the ACE Integrase, a proprietary version of the lambda phage integrase that has been genetically engineered to function in mammalian cells without bacterial cofactors (Figure 1), resulting in the generation of two new sites, attR and attL. The ACE Integrase reaction is unidirectional and catalyzes only the integration of the ATV onto the Platform ACE because it lacks the bacterial cofactors required for excision. The combination of multiple attP sites on the Platform ACE and the unidirectional ACE Integrase enables multiple loadings (during a single transfection) or sequential loadings (via multiple transfections) with ATVs. Moreover, the ATV itself has a considerable carrying capacity and has been able to carry payloads exceeding 1.25 Mbp.

The ACE System targeted integration increases the efficiency of screening; only cells in which the ATV has correctly integrated into the Platform ACE are selected. Because multiple gene copies are inserted in a single round of loading into a consistent molecular environment, very few colonies (100–200) have to be screened to identify the high-expressing clones.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here